Voices
Aya Mohamed: Neoadjuvant Palbociclib + ET vs Chemotherapy in ER+/HER2− Breast Cancer
Aya Mohamed/X

Aya Mohamed: Neoadjuvant Palbociclib + ET vs Chemotherapy in ER+/HER2− Breast Cancer

Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared a post on X:

“Phase II randomized trial: Neoadjuvant palbociclib + ET vs chemotherapy in ER+/HER2−Breast Cancer.

Superior Ki-67 suppression potent cell-cycle arrest Comparable clinical response, with low pCR in both arms.”

Title: Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

Authors: Alexios Matikas, Evangelos Tzoras, Michail Sarafidis, Emmanouil G. Sifakis, Judith Bjöhle, Elin Barnekow, Sara Margolin, Erika Isaksson-Friman, Luisa Edman Kessler, Athanasios Zouzos, Hemming Johansson, Mats Hellström, Susanne Agartz, Per Grybäck, Dimitrios Salgkamis, Ioannis Zerdes, Kang Wang, Johan Hartman, Balazs Acs, Wenwen Sun, Ceren Boyaci, Guillermo Villacampa, Tomas Pascual, Joaquin Gavila, Theodoros Foukakis

Read the full article on Nature Communications.

Aya Mohamed: Neoadjuvant Palbociclib + ET vs Chemotherapy in ER+/HER2− Breast Cancer

Other articles featuring Aya Mohamed on OncoDaily.

Alexios Matikas Athanasios Zouzos Aya Mohamed Balazs Acs Breast Cancer cancer Ceren Boyaci Dimitrios Salgkamis Elin Barnekow Emmanouil G. Sifakis Erika Isaksson-Friman Evangelos Tzoras Guillermo Villacampa Hemming Johansson Ioannis Zerdes Joaquín Gavilá Johan Hartman Judith Bjöhle Kang Wang Luisa Edman Kessler Mats Hellström Michail Sarafidis OncoDaily Oncology Per Grybäck Sara Margolin Susanne Agartz Theodoros Foukakis Tomás Pascual Wenwen Sun